| Login
| Connect 
Top Analyst Boosts Price Target for Aldeyra Therapeutics Inc (ALDX); Here’s Why
Ritu Baral sees 35% upside for Aldeyra on back of positive Phase 2a dry eye study.
Top Analyst Shines Light on Intercept Pharmaceuticals Inc’s (ICPT) Dear Health Care Provider Letter
Dear doctor: My shares just fell 15%.
Analysts Punish Otonomy Inc (OTIC) in Wake of Meniere’s Disease Drug Failure
Wednesday turned out to be a nightmare for Otonomy Inc (NASDAQ:OTIC) investors, after the drug …
Juno Therapeutics Inc (JUNO) Looks Well Positioned in Light of KITE Takeout: Top Analyst
David Nierengarten Re-evaluates JUNO; Upgrades Shares to Outperform
Chardan Bullish on The Medicines Company (MDCO); Reiterates $85 Price Target
In a research report issued Wednesday, Chardan analyst Gbola Amusa reiterated a Buy rating on …
Oppenheimer Comments on The Medicines Company (MDCO) Following FDA Approval for VABOMERE
The Medicines Company’s Vabomere – A Solid Option for CarbapenemResistant cUTIs: Oppenheimer
Ultragenyx Pharmaceutical Inc (RARE) Tumbles on Ace-ER Failure; Top Analyst Remains Bullish
Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM
Cantor Bets on Opko Health Inc. (OPK); Sees 240% Upside
Looking for a reason to buy shares of Opko Health Inc. (NASDAQ:OPK)? How about three …
Cantor Shines Light on TherapeuticsMD Inc (TXMD) Following Publication of Clinical Data in Menopause
Cantor analyst William Tanner is out today with a few insights on TherapeuticsMD Inc (NYSEMKT:TXMD), after the …